Clinical significance of serum retinol binding protein-4 levels in patients with systemic sclerosis

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 3, 2013, Pages 337-344

  Toyama, T ^a   Asano, Y ^a   Takahashi, T ^a   Aozasa, N ^a   Akamata, K ^a   Noda, S ^a   Taniguchi, T ^a   Ichimura, Y ^a   Sumida, H ^a   Tamaki, Z ^a   Masui, Y ^a   Tada, Y ^a   Sugaya, M ^a   Sato, S ^a   Kadono, T ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; RETINOL BINDING PROTEIN 4;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSIS; GLOMERULUS FILTRATION RATE; HEART RIGHT VENTRICLE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAYNAUD PHENOMENON; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE;

CYCLOPHOSPHAMIDE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RAYNAUD DISEASE; RETINOL-BINDING PROTEINS, PLASMA; SCLERODERMA, SYSTEMIC;

EID: 84874105740     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04413.x     Document Type: Article

References (27)

1. Asano Y,. Future treatments in systemic sclerosis. J Dermatol 2010; 37: 54-70.
2. Shepherd PR, Kahn BB,. Glucose transporters and insulin action-implications for insulin resistance and diabetes mellitus. N Engl J Med 1999; 341: 248-257.
3. Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436: 356-362.
4. Alkhouri N, Lopez R, Berk M, et al. Serum retinol-binding protein 4 levels in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol 2009; 43: 985-989.
5. Nobili V, Alkhouri N, Alisi A, et al. Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 575-579.
6. Kwon JH, Park ST, Kim GD, et al. The value of serum retinol-binding protein 4 levels for determining disease severity in patients with chronic liver disease. Korean J Hepatol 2009; 15: 59-69.
7. Iwasa M, Hara N, Miyachi H, et al. Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels. J Viral Hepat 2009; 16: 716-723.
8. Takebayashi K, Sohma R, Aso Y, et al. Effects of retinol binding protein 4 on vascular endothelial cells. Biochem Biophys Res Commun 2011; 408: 58-64.
9. Masui Y, Asano Y, Shibata S, et al. Serum adiponectin levels inversely correlate with the activity of progressive skin sclerosis in patients with diffuse cutaneous systemic sclerosis. J Eur Acad Dermatol Venereol 2011; doi: 10.1111/j.1468-3083.2011.04077.x. [Epub ahead of print].
10. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-205.
11. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-590.
12. Clements PJ, Lachenbruch PA, Seibold JR, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20: 1892-1896.
13. Asano Y, Ihn H, Yamane K, et al. The prevalence and clinical significance of anti-U1 RNA antibodies in patients with systemic sclerosis. J Invest Dermatol 2003; 120: 204-210.
14. Kazerooni EA, Martinez FJ, Flint A, et al. Thin-section CT obtained at 10-mm increments vs. limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997; 169: 977-983.
15. Masaki T, Anan F, Tsubone T, et al. Retinol binding protein 4 concentrations are influenced by renal function in patients with type 2 diabetes mellitus. Metabolism 2008; 57: 1340-1344.
16. Henze A, Frey SK, Raila J, et al. Evidence that kidney function but not type 2 diabetes determines retinol-binding protein 4 serum levels. Diabetes 2008; 57: 3323-3326.
17. Cabré A, Lázaro I, Girona J, et al. Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes. J Intern Med 2007; 262: 496-503.
18. Steen VD, Medsger TA,. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-2444.
19. Broch M, Ramírez R, Auguet MT, et al. Macrophages are novel sites of expression and regulation of retinol binding protein 4 (RBP4). Physiol Res 2010; 59: 299-303.
20. Taylor KR, Yamasaki K, Radek KA, et al. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. J Biol Chem 2007; 282: 18265-18275.
21. Yoshizaki A, Iwata Y, Komura K, et al. Clinical significance of serum hyaluronan levels in systemic sclerosis: association with disease severity. J Rheumatol 2008; 35: 1825-1829.
22. Rosenblum WD,. Pulmonary arterial hypertension: pathobiology, diagnosis, treatment, and emerging therapies. Cardiol Rev 2010; 18: 58-63.
23. Vancheeswaran R, Magoulas T, Efrat G, et al. Circulating endothelin-1 levels in systemic sclerosis subsets-a marker of fibrosis or vascular dysfunction? J Rheumatol 1994; 21: 1838-1844.
24. Denton CP, Humbert M, Rubin L, et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006; 65: 1336-1340.
25. McLaughlin VV,. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur J Clin Invest 2006; 36 (Suppl 3): 10-15.
26. Williams MH, Das C, Handler CE, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006; 92: 926-932.
27. Arakawa H, Jinnin M, Muchemwa FC, et al. Adiponectin expression is decreased in the involved skin and sera of diffuse cutaneous scleroderma patients. Exp Dermatol 2011; 20: 764-766.